Want to see JP:7702 full AI Analyst Report?
7702 Stock Chart & Stats
¥442.00
-¥3.00(-0.69%)
At close: 4:00 PM EST
¥442.00
-¥3.00(-0.69%)
Day’s Range― - ―
52-Week Range¥418.00 - ¥478.00
Previous CloseN/A
Volume24.60K
Average Volume (3M)25.96K
Market Cap
¥11.19B
Enterprise Value¥31.13B
Total Cash (Recent Filing)¥7.72B
Total Debt (Recent Filing)¥28.01B
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.77%
Share Statistics
EPS (TTM)-31.94
Shares Outstanding24,733,465
10 Day Avg. Volume29,090
30 Day Avg. Volume25,963
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.16
P/FCF Ratio-11.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables BusinessJMS's core revenue is anchored in single‑use medical consumables consumed each procedure, creating recurring reorder streams tied to routine clinical activity. That structural demand reduces revenue cyclicality, supports predictable unit volumes, and underpins durable cash inflows as adoption expands.
Moderate Balance-sheet Equity BufferThe company’s sizable equity base relative to debt provides a tangible buffer to absorb earnings volatility or one-off shocks, supporting liquidity and creditor confidence. That balance‑sheet scale helps preserve operational continuity while management executes margin recovery or strategic investments.
Consistent Operating Cash GenerationPositive operating cash flow across reported years signals the underlying business converts sales into cash despite earnings swings. Reliable OCF supports working‑capital needs, funds selective capex or dividends, and provides a base from which management can prioritize deleveraging or targeted growth initiatives.
Bears Say
Deteriorating ProfitabilityMargins and earnings power have weakened materially versus prior years, culminating in a net loss. This erosion reduces internal cash available for reinvestment, undermines the business’s ability to finance growth initiatives organically, and constrains options for sustained margin restoration.
Volatile And Often Negative Free Cash FlowRepeated negative free cash flow, including a decline to ‑¥0.9B in 2026, limits organic deleveraging and forces reliance on external financing or balance‑sheet resources. Persistent FCF weakness hampers investment capacity, reduces strategic flexibility and raises execution risk for recovery plans.
Rising Leverage Reduces FlexibilityAn upward trend in leverage tightens financial flexibility and increases sensitivity to revenue or margin disappointments. Higher debt amplifies refinancing and interest‑cost risk, potentially crowding out necessary R&D or commercial investment and making sustained margin recovery more difficult.
JMS Co., Ltd. News
7702 FAQ
What was JMS Co., Ltd.’s price range in the past 12 months?
JMS Co., Ltd. lowest stock price was ¥418.00 and its highest was ¥478.00 in the past 12 months.
What is JMS Co., Ltd.’s market cap?
JMS Co., Ltd.’s market cap is ¥11.19B.
When is JMS Co., Ltd.’s upcoming earnings report date?
JMS Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 9 days.
How were JMS Co., Ltd.’s earnings last quarter?
JMS Co., Ltd. released its earnings results on May 12, 2026. The company reported -¥27.71 earnings per share for the quarter, missing the consensus estimate of N/A by -¥27.71.
Is JMS Co., Ltd. overvalued?
According to Wall Street analysts JMS Co., Ltd.’s price is currently Overvalued.
Does JMS Co., Ltd. pay dividends?
JMS Co., Ltd. pays a Semiannually dividend of ¥8.5 which represents an annual dividend yield of 3.77%. See more information on JMS Co., Ltd. dividends here
What is JMS Co., Ltd.’s EPS estimate?
JMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JMS Co., Ltd. have?
JMS Co., Ltd. has 24,733,465 shares outstanding.
What happened to JMS Co., Ltd.’s price movement after its last earnings report?
JMS Co., Ltd. reported an EPS of -¥27.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.179%.
Which hedge fund is a major shareholder of JMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7702
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JMS Co., Ltd.
JMS Co., Ltd., established in 1947 and headquartered in Hiroshima, Japan, specializes in the development, manufacture, distribution, and global trade of a wide array of medical devices and pharmaceuticals. Its extensive product catalog serves both Japanese and international markets, addressing diverse medical needs. The company provides a comprehensive range of items for infusion and transfusion therapy, including infusion/transfusion sets (some featuring needle-free access ports), single-use needles and syringes, secure scalp vein sets, safe intravenous catheters, extension tubing, oral and enteral feeding systems, infusion and syringe delivery pumps, devices for administering semi-solid nutritional supplements, as well as blood bags, blood collection scales and mixers, high-frequency tube sealing equipment, and serum collection apparatus. For general medical use, JMS offers essential consumables for healthcare institutions such as surgical and examination gloves (both latex and plastic), treatment drapes, surgical gowns, protective masks and caps, drainage receptacles, and surgical adhesive tapes. Furthermore, JMS is a key supplier for hemodialysis and peritoneal dialysis, providing centralized dialysate delivery systems, hemodialysis units, AV fistula needles, systems designed to prevent accidental needlestick injuries, blood tubing sets for hemodialysis, dialyzers, pre-filled syringes, complete hemodialysis kits, single-patient dialysis devices, dialysis solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD), and automated peritoneal dialysis equipment. The company also offers specialized products for cardiovascular therapy, which encompass cardiopulmonary support systems, membrane oxygenators, heat exchange units, pacemakers, microcatheters, and blood tubing sets for cardiopulmonary bypass.